|
32 Companies |
|
48 Products |
|
48 Products |
|
52 Mechanisms of Action |
|
0 Trials |
|
99 News |
|
| 12» |
- | Leukine (sargramostim) / Partner Therap
Enrollment change, Trial withdrawal: Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma (clinicaltrials.gov) - Nov 26, 2018
P2, N=0, Withdrawn, Sponsor: University of Texas Southwestern Medical Center
N=30 --> 0 | Recruiting --> Withdrawn
- | capecitabine / Generic mfg.
Trial completion: Irinotecan and Capecitabine in Treating Patients With Solid Tumors (clinicaltrials.gov) - Sep 10, 2018
P1, N=30, Completed, Sponsor: Montefiore Medical Center
N=30 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Completed
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment change, Trial completion date, Trial termination, Combination therapy, Metastases: FluoHeart: Effects of S-1 and Capecitabine on Coronary Artery Blood Flow (clinicaltrials.gov) - Aug 28, 2018
P2, N=20, Terminated, Sponsor: Heikki Joensuu
Active, not recruiting --> Completed N=40 --> 20 | Trial completion date: Aug 2019 --> Aug 2018 | Recruiting --> Terminated; Slow accrual
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Grant: Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer (clinicaltrials.gov) - Aug 16, 2018
P2, N=60, Completed, Sponsor: Montefiore Medical Center
N=40 --> 20 | Trial completion date: Aug 2019 --> Aug 2018 | Recruiting --> Terminated; Slow accrual Active, not recruiting --> Completed
- | Trial completion, IO biomarker: Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma (clinicaltrials.gov) - Mar 12, 2018
P=N/A, N=30, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Enrollment change, Trial initiation date, Trial termination: Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine (clinicaltrials.gov) - Sep 29, 2017
P2, N=1, Terminated, Sponsor: Burzynski Research Institute
Active, not recruiting --> Completed N=40 --> 1 | Initiation date: Aug 1998 --> Aug 1997 | Active, not recruiting --> Terminated; slow accrual
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg., capecitabine / Generic mfg.
Biomarker, Trial completion, Metastases: Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer (clinicaltrials.gov) - Aug 24, 2017
P2, N=33, Completed, Sponsor: Alliance for Clinical Trials in Oncology
N=40 --> 1 | Initiation date: Aug 1998 --> Aug 1997 | Active, not recruiting --> Terminated; slow accrual Active, not recruiting --> Completed
- | oxaliplatin / Generic mfg., erlotinib / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Metastases: Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer (clinicaltrials.gov) - Jul 2, 2017
P1, N=28, Completed, Sponsor: Vanderbilt-Ingram Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, Trial completion, Enrollment change, Trial primary completion date, Metastases: Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - May 25, 2017
P1, N=7, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=70 --> 7 | Trial primary completion date: Jun 2016 --> Nov 2010
- | Trial completion, HEOR: Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer (clinicaltrials.gov) - May 24, 2017
P=N/A, N=144, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed | N=70 --> 7 | Trial primary completion date: Jun 2016 --> Nov 2010 Active, not recruiting --> Completed
- | Trial completion, Enrollment change, Trial primary completion date: Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 22, 2017
P=N/A, N=17, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=100 --> 17 | Trial primary completion date: Dec 2016 --> Feb 2012
- Trial primary completion date, IO biomarker: Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma (clinicaltrials.gov) - Oct 17, 2016
P=N/A, N=31, Active, not recruiting, Sponsor: Craig Hofmeister
Active, not recruiting --> Completed | N=100 --> 17 | Trial primary completion date: Dec 2016 --> Feb 2012 Trial primary completion date: Nov 2012 --> Jul 2011
- Trial completion: Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer (clinicaltrials.gov) - Aug 15, 2016
P2, N=7, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Nov 2012 --> Jul 2011 Terminated --> Completed
- | Epogen (epoetin alfa) / Amgen
Trial completion: Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy (clinicaltrials.gov) - Jul 11, 2016
P3, N=344, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Terminated --> Completed No longer recruiting --> Completed
- | ondansetron / Generic mfg.
Trial completion, Metastases: Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment (clinicaltrials.gov) - Jul 4, 2016
P3, N=100, Completed, Sponsor: Alliance for Clinical Trials in Oncology
No longer recruiting --> Completed Active, not recruiting --> Completed
- oxaliplatin / Generic mfg., erlotinib / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed, Metastases: Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer (clinicaltrials.gov) - Jun 29, 2016
P1, N=28, Active, not recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Active, not recruiting --> Completed Completed --> Active, not recruiting
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, Trial primary completion date, Metastases: Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Apr 21, 2016
P1, N=70, Active, not recruiting, Sponsor: Mayo Clinic
Completed --> Active, not recruiting Trial primary completion date: Jun 2015 --> Jun 2016
- Trial primary completion date: Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Apr 19, 2016
P=N/A, N=100, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Jun 2015 --> Jun 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- Trial completion: Vegetable Garden Feasibility Trial to Promote Function in Older Cancer Survivors (clinicaltrials.gov) - Feb 9, 2016
P=N/A, N=46, Completed, Sponsor: University of Alabama at Birmingham
Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed
- Trial termination: Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer (clinicaltrials.gov) - Oct 3, 2015
P2, N=7, Terminated, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Completed --> Terminated; Slow accrual
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Sep 30, 2015
P1, N=43, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Slow accrual Active, not recruiting --> Completed
- oxaliplatin / Generic mfg., irinotecan / Generic mfg., capecitabine / Generic mfg.
Biomarker, Trial primary completion date, Metastases: Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer (clinicaltrials.gov) - Sep 22, 2015
P2, N=33, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Trial primary completion date: Dec 2012 --> Dec 2014
- Enrollment change: Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer (clinicaltrials.gov) - Aug 26, 2015
P=N/A, N=180, Terminated, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Dec 2012 --> Dec 2014 N=150 --> 180
- Trial completion, Trial primary completion date, Metastases: High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Aug 26, 2015
P1, N=33, Completed, Sponsor: City of Hope Medical Center
N=150 --> 180 Active, not recruiting --> Completed | Trial primary completion date: Feb 2016 --> Aug 2015
- oxaliplatin / Generic mfg., irinotecan / Generic mfg., capecitabine / Generic mfg.
Biomarker, Enrollment closed, Metastases: Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer (clinicaltrials.gov) - Aug 13, 2015
P2, N=33, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | Trial primary completion date: Feb 2016 --> Aug 2015 Recruiting --> Active, not recruiting
- Trial completion, Enrollment change, Trial primary completion date: Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer (clinicaltrials.gov) - Jul 9, 2015
P2, N=7, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=75 --> 7 | Trial primary completion date: Aug 2011 --> Jan 2011
- | oxaliplatin / Generic mfg., capecitabine / Generic mfg.
Trial completion, Combination therapy: Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer (clinicaltrials.gov) - Apr 27, 2015
P1, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=75 --> 7 | Trial primary completion date: Aug 2011 --> Jan 2011 No longer recruiting --> Completed
- | alvocidib (DSP-2033) / Sumitomo Pharma
Trial completion: Flavopiridol in Treating Patients With Refractory Cancer (clinicaltrials.gov) - Apr 27, 2015
P1, N=0, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Not yet recruiting --> Completed
- | Trial completion: Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - Apr 27, 2015
P1, N=24, Completed, Sponsor: National Institute on Aging (NIA)
Not yet recruiting --> Completed Suspended --> Completed
- || Trial primary completion date: Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Apr 19, 2015
P=N/A, N=100, Active, not recruiting, Sponsor: Mayo Clinic
Suspended --> Completed Trial primary completion date: Dec 2014 --> Dec 2015
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment open, Trial initiation date, Combination therapy, Metastases: FluoHeart: Effects of S-1 and Capecitabine on Coronary Artery Blood Flow (clinicaltrials.gov) - Apr 8, 2015
P2, N=40, Recruiting, Sponsor: Heikki Joensuu
Trial primary completion date: Dec 2014 --> Dec 2015 Not yet recruiting --> Recruiting | Initiation date: Aug 2014 --> Jan 2015
- Trial primary completion date, Metastases: High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Dec 24, 2014
P1, N=6, Active, not recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting | Initiation date: Aug 2014 --> Jan 2015 Trial primary completion date: Feb 2015 --> Feb 2016
- Trial completion, Enrollment change, Trial primary completion date, Metastases: Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients (clinicaltrials.gov) - Dec 19, 2014
P=N/A, N=329, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
Trial primary completion date: Feb 2015 --> Feb 2016 Active, not recruiting --> Completed | N=450 --> 329 | Trial primary completion date: May 2013 --> Sep 2013
- ||| Trial completion, Trial primary completion date: CELSIUS: Capsule Endoscopy to Screen for Small Bowel Neoplasia in Lynch Syndrome (clinicaltrials.gov) - Dec 10, 2014
P0, N=200, Completed, Sponsor: University Medical Centre Groningen
Active, not recruiting --> Completed | N=450 --> 329 | Trial primary completion date: May 2013 --> Sep 2013 Enrolling by invitation --> Completed | Trial primary completion date: May 2012 --> Dec 2014
- Enrollment closed: Vegetable Garden Feasibility Trial to Promote Function in Older Cancer Survivors (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=46, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Enrolling by invitation --> Completed | Trial primary completion date: May 2012 --> Dec 2014 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Phase classification, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Sep 28, 2014
P1, N=43, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Phase classification: P1/2 --> P1
- | Cilcane (cilengitide) / Iceni Pharma
Trial completion, Metastases: EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer (clinicaltrials.gov) - Sep 17, 2014
P1, N=40, Completed, Sponsor: Indiana University School of Medicine
Phase classification: P1/2 --> P1 Active, not recruiting --> Completed
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Combination therapy, Metastases: FluoHeart: Effects of S-1 and Capecitabine on Coronary Artery Blood Flow (clinicaltrials.gov) - Aug 15, 2014
P2, N=40, Not yet recruiting, Sponsor: Heikki Joensuu
- Trial termination, Trial primary completion date: Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer (clinicaltrials.gov) - Jul 24, 2014
P=N/A, N=150, Terminated, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Suspended --> Terminated | Trial primary completion date: Dec 2014 --> Sep 2012; Study due for continuing review
- || Enrollment closed: Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jul 15, 2014
P=N/A, N=100, Active, not recruiting, Sponsor: Mayo Clinic
Suspended --> Terminated | Trial primary completion date: Dec 2014 --> Sep 2012; Study due for continuing review Recruiting --> Active, not recruiting
- | Trial completion, Metastases: 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma (clinicaltrials.gov) - Feb 22, 2014
P1, N=40, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Onrigin (laromustine) / Vion
Trial completion, Metastases: VNP40101M in Treating Patients With Advanced or Metastatic Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=0, Completed, Sponsor: Vion Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | thalidomide / Generic mfg., docetaxel / Generic mfg.
Trial completion, Metastases: Thalidomide and Docetaxel in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=26, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | lenalidomide / Generic mfg., thalidomide / Generic mfg.
Trial completion, Metastases: CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy (clinicaltrials.gov) - Feb 22, 2014
P1, N=0, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | paclitaxel / Generic mfg.
Trial completion, Metastases: Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas (clinicaltrials.gov) - Feb 19, 2014
P1, N=70, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | cisplatin / Generic mfg., capecitabine / Generic mfg.
Trial completion, Metastases: Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: New York University School of Medicine
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Nuvion (visilizumab) / PDL
Trial completion, Metastases: Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Stanford University
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | cyclophosphamide / Generic mfg.
Trial completion: Bone Marrow Transplantation in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Completed Active, not recruiting --> Completed
- | azacitidine / Generic mfg., sodium phenylbutyrate / Generic mfg.
Trial completion, Combination therapy, Metastases: Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | Zolinza (vorinostat) / Merck (MSD)
Trial completion, Metastases: Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Completed Active, not recruiting --> Completed